[Application of SPECT/PET to 70 Patients with Lymphoma: Monitoring Response to Therapy].

Hui Yao,Xi-Nan Cen,Ze-Yin Liang,Jin-Ping Ou,Zhi-Xiang Qiu,Wen-Sheng Wang,Wei-Lin Xu,Yuan Li,Yue Yin,Mang-Ju Wang,Yu-Jun Dong,Li-Hong Wang,Han-Yun Ren
2010-01-01
Abstract:OBJECTIVE To evaluate the image of SPECT/PET (18)F-FDG in monitoring response to therapy for lymphoma patients. METHODS A retrospective study was performed in 83 SPECT/PET studies for 70 patients with lymphoma from 1998 to 2008 in our hospital. The risk factors for survival rate were analyzed by univariate analysis. RESULTS Forty patients received SPECT/PET after 2 - 4 cycles of chemotheraphy, the median PFS in patients with positive and negative group were 5.5 months and 15.5 months, 2-year PFS were 12.5% and 66.8%; the median OS were 12.5 months and 17 months, and 1-year OS were 28.8% and 94.1%, respectively, all being of significant difference between two groups (P = 0.003). Forty-three patients performed posttreatment SPECT/PET, the median PFS in patients with positive and negative group were 10 months and 23 months, the 2-year PFS were 23.3% and 83.2%; the median OS were 17 months and 27 months and the 2-year OS were 60.0% and 100% respectively, all being of significant difference (P = 0.001). CONCLUSION SPECT/PET has significant value in monitoring response to therapy and predicting prognosis for patients with lymphoma.
What problem does this paper attempt to address?